EGFR-targeting Chimeric Monoclonal IgG-1 Antibody Cetuximab in a Phase II/III Study Added Either to Gemcitabine Followed by Docetaxel or Carboplatin Plus Gemcitabine for Chemonaive Patients With Advanced Non-small Cell Lung Cancer (NSCLC) - Results of the Phase II Study Part
EUROPEAN JOURNAL OF CANCER（2011）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined